PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33965356-0	2021	Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant.	uridine triacetate	7-25	dihydropyrimidine dehydrogenase	Homo sapiens	148-152	
27716991-4	2016	To our knowledge, this is the first case report that documents the clinical course of a patient treated with uridine triacetate to reverse early-onset 5-FU toxicity negative for DPD mutations.	uridine triacetate	109-127	dihydropyrimidine dehydrogenase	Homo sapiens	178-181	
27278667-5	2016	PATIENTS AND METHODS: We identified two patients with advanced pancreatic cancer who were referred to us for testing of DPYD status following severe toxicity associated with 5-FU administered at a dose of 1400 mg/m(2) weekly bolus high-dose 5-FU followed by oral uridine triacetate as a part of a clinical trail.	uridine triacetate	263-281	dihydropyrimidine dehydrogenase	Homo sapiens	120-124